The recurrence risk in pediatric noninfectious uveitis during adalimumab tapering: are we rigorous enough?

Documenti analoghi

• Variation in the incidence of juvenile idiopathic arthritis in Norway as latitude changes: are we rigorous enough? Comment on the article by Hestetun et al
  di: Sheng Qiu, et al.
  Pubblicazione: (2025)
• Concordance between ultrasound and physical examination in enthesitis assessment: a call for further investigation: comment on the article by Di Matteo et al
  di: Danxiang Shen, et al.
  Pubblicazione: (2025)
• Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to JAK inhibitors versus adalimumab: a nationwide cohort study: comment on the article by Hoisnard et al
  di: Jing‐jin Hu, et al.
  Pubblicazione: (2025)
• Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial
  di: Po‐Cheng Shih, et al.
  Pubblicazione: (2025)
• Unexplored limitations in a randomized trial that examines efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: comment on the article by Merrill et al
  di: Qianyu Guo, et al.
  Pubblicazione: (2025)